Immune combo shows promise in tough ovarian cancer
NCT ID NCT03245892
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 30 times
Summary
This early-phase study tested whether adding immune drugs (nivolumab alone or with ipilimumab) to standard chemotherapy is safe for people with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. 27 participants received the combination before and after surgery. The main goal was to check for serious side effects, not to measure long-term disease control or cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.